Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan
October 3, 2024 6:01 AM EDTJPMorgan analyst Tessa Romero raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $55.00) while maintaining a Overweight rating.
The analyst comments "We are updating our model following Biohavens updates last week around their troriluzole program in spinocerebellar ataxia (SCA), where the company expects to complete resubmission of an NDA for the treatment of all SCA genotypes... More
